-
ASCO | Professor Ming Chen: R-ALPS Study Validates the “Dual Maintenance” Strategy, Offering a Chinese Solution for Locally Advanced NSCLC
This Phase III clinical trial is the first to explore a “dual maintenance” strategy using the domestic PD-L1 inhibitor bemosotamab in combination with the anti-angiogenic agent anlotinib. The results showed…
-
ASCO | Professor Jieqiong Liu: Unveiling a New Path in Metastatic Breast Cancer Treatment—Dissecting the Tumor Microenvironment in Combination Therapy
This study focused on the efficacy and safety of the combination therapy KN046 and KN026 in patients with HER2-positive breast cancer who had failed second-line or later treatments. Using single-cell…
-
ASCO China Voice | Prof. Haiqiang Mai: Domestic PD-L1 Inhibitor Tagitinlimab Shows New Strength as First-Line Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma (NPC) is a malignancy with high prevalence in Southern China and other Southeast Asian countries, imposing a significant disease burden. Treatment options for recurrent/metastatic NPC (R/M NPC) remain limited. In recent years, immune checkpoint inhibitors (ICIs) have brought new hope to this patient population, and domestically developed ICIs in China have demonstrated promising…
-
National Open Day Event at the National Key Laboratory of Hematology and Health, 2025
In celebration of the 2025 National Science and Technology Workers Day and International Children’s Day, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College hosted a public science outreach event as part of the National Open Day at the National Key Laboratory of Hematology and Health. Over…
-
ASCO China Voice | Prof. Yehui Shi: Utidelone Combination Offers New Hope for Patients with HER2-Negative Breast Cancer and Brain Metastases
This study addresses the current lack of effective systemic treatments for HER2-negative brain metastases, a particularly challenging subtype where standard therapies offer limited benefit due to the restrictive nature of…
-
ASCO China Voice | Prof. Yan Huang’s Team Reports Phase I Results of BL-B01D1, Paving a New Path in Precision Therapy for SCLC
At the ongoing 2025 ASCO Annual Meeting, Professor Yan Huang from Sun Yat-sen University Cancer Center delivered an oral presentation (Abstract #3002) on the results of a Phase I study…
-
ASCO China Voice | Prof. Kefeng Ding: ANCHOR Study Offers a New First-Line Treatment Option for RAS/BRAF Wild-Type Metastatic Colorectal Cancer
Oncology Frontier: Could you share the background and design rationale of the ANCHOR study? Prof. Kefeng Ding: In our previous Phase II single-arm exploratory trial, we observed that the combination…
Connecting Medical Expertise through Media
